Last Updated: November 16, 2026

Details for Patent: 12,679,836

« Back to Dashboard


Which drugs does patent 12,679,836 protect, and when does it expire?

Patent 12,679,836 protects HYRNUO and is included in one NDA.

This patent has forty patent family members in thirty-four countries.

Summary for Patent: 12,679,836
Title:4H-pyrrolo[3,2-c]pyridin-4-one compounds
Abstract:Compounds of formula (I), formula (I), processes for their production and their use as pharmaceuticals.
Inventor(s):Stephan Siegel, Franziska SIEGEL, Volker Schulze, Markus Berger, Keith Graham, Detlev Sülzle, Ulf Bömer, Daniel Korr, Jens Schröder, Ursula Mönning, Michael Niehues, Matthew Meyerson, Heidi Greulich, Bethany Kaplan
Assignee: Bayer AG , Dana Farber Cancer Institute Inc , Broad Institute
Application Number:US17/605,975
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 12,679,836

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Healthcare HYRNUO sevabertinib TABLET;ORAL 219972-001 Nov 19, 2025 RX Yes Yes 12,679,836 ⤷  Start Trial Y Y TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE HER2 (ERBB2) TYROSINE KINASE DOMAIN (TKD) ACTIVATING MUTATIONS AND WHO HAVE RECEIVED A PRIOR SYSTEMIC THERAPY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,679,836

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 118748 ⤷  Start Trial
Australia 2020262221 ⤷  Start Trial
Brazil 112021019998 ⤷  Start Trial
Canada 3137218 ⤷  Start Trial
Chile 2021002770 ⤷  Start Trial
China 114127064 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.